Results 161 to 170 of about 23,469,807 (290)
From Retrofitting to Adaptive Fitting: Time Scale and Locus of Change Capacity in Adaptive and Demountable Building Envelopes. [PDF]
Çınar Z.
europepmc +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
The anticipation of imminent events is time-scale invariant. [PDF]
Grabenhorst M, Poeppel D, Michalareas G.
europepmc +1 more source
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source
Nonlinear reversal of photoexcitation on the attosecond time scale improves ultrafast X-ray diffraction images. [PDF]
Ulmer A +30 more
europepmc +1 more source
Functional plasticity in chromosome-microtubule coupling on the evolutionary time scale. [PDF]
Sankaranarayanan SR +7 more
europepmc +1 more source
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Publisher Correction: Hydrogen storage capacity planning and system balance analysis based on multi time scale adjustment of demand probability distribution. [PDF]
Jiang K +7 more
europepmc +1 more source
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source

